FINWIRES · TerminalLIVE
FINWIRES

摩根士丹利表示,Tenable有望受益于人工智能需求,但转化率仍然至关重要。

By

-- 摩根士丹利周四在一份报告中指出,Tenable (TENB) 有望受益于人工智能驱动的安全需求增长和风险敞口管理应用的普及,但投资者可能仍将持观望态度,直到有更明确的证据表明,这些潜在兴趣能够转化为持续的订单和收入增长。 该投资公司表示,Tenable 第一季度业绩稳健,并略微上调了全年预期,但隐含的增长轨迹仍然表明,今年晚些时候增长势头可能会放缓。 摩根士丹利表示,随着企业应对日益扩大的安全威胁面,人工智能正在显著提升客户兴趣,但这些讨论仍需转化为实际的签约交易。 该投资公司补充道,鉴于对隐含增长放缓、净留存率下降以及核心漏洞管理市场持续承压(包括来自人工智能原生竞争对手的潜在冲击)的担忧,投资者可能会继续保持谨慎态度。 报告指出,Tenable One 和风险敞口管理仍然是其关键优势领域,Tenable One 在第一季度的新业务中占比 41%,企业客户新增数量也保持良好势头。摩根士丹利维持对Tenable的“中性”评级,并将目标股价从30美元下调至27美元,称正在等待更确凿的证据,证明人工智能驱动的需求能够转化为持续的增长。 周四下午交易中,Tenable股价下跌1.8%。

Price: $21.08, Change: $-0.40, Percent Change: -1.84%

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM